摘要
目的:观察五酯胶囊联合他克莫司治疗乙型肝炎病毒相关性肾炎临床效果。方法:采用前瞻性完全随机对照试验,观察2015年7月至2018年8月至潍坊医学院附属医院就诊的HBV-GN患者。将符合纳入标准的62例患者依据随机数字表法分为治疗组33例和对照组29例。治疗组患者采用五酯胶囊联合他克莫司和恩替卡韦治疗12个月,对照组则采用恩替卡韦单药治疗12个月。应用统计学方法分析ALT、AST、ALB、uTP(24h)、Scr、HBV DNA滴度等指标,探讨五酯胶囊联合他克莫司和恩替卡韦治疗乙型肝炎病毒相关性肾炎临床疗效。结果:治疗组12个月后总缓解率为87.88%,对照组为62.07%(P<0.05),差异有统计学意义。治疗组血清ALT、AST、ALB、uTP(24h)在治疗6个月、12个月后改善明显优于对照组(P<0.05),差异有统计学意义。治疗组HBV DNA滴度下降,治疗12个月前后比较,差异有统计学意义(P<0.05)。肌酐值在治疗前后无明显变化,差异无统计学意义(P>0.05)。结论:五酯胶囊联合他克莫司和恩替卡韦能有效诱导HBV-GN缓解,更好保护肝肾功能,安全性好,值得临床借鉴。
Objective:To observe the effect of Wuzhi capsule combined with tacrolimus on hepatitis B virus-associated nephritis.Methods:The prospective randomized controlled trial was used to observe the HBV-GN patients who visited the Affiliated Hospital of Weifang Medical College from July 2015 to August 2018.62 patients meeting the inclusion criteria were divided into treatment group(33 cases)and control group(29 cases).Patients in the treatment group were treated with Wuzhi capsule combined with tacrolimus and entecavir for 12 months,while those in the control group were treated with entecavir alone for 12 months.Alt,AST,ALB,UTP(24h),SCR,HBV DNA titer were analyzed by statistical method.The clinical efficacy of Wuzhi capsule combined with tacrolimus and entecavir in the treatment of hepatitis B-related nephritis was studied.Results:The total remission rate of Wuzhi capsule combined with tacrolimus and entecavir was 87.88%after 12 months,compared with 62.07%in entecavir group(P<0.05).The serum levels of ALT,AST,ALB,and uTP(24h)in the treatment group were significantly better than those in the control group at 6 and 12 months(P<0.05).After 12 months of treatment,HBV DNA titer decreased in the treatment group,and the difference was statistically significant(P<0.05).The Scr value was no significant change after treatment,there was no difference(P>0.05).Conclusion:Wuzhi capsule combined with tacrolimus and entecavir can effectively induce the remission of HBV-GN,better protect the function of liver and kidney,and have good safety,which is worthy of clinical reference.
作者
赵睿
戚丽
ZHAO Rui;QI Li(Weifang Medical College, Shandong Weifang 261000, China)
出处
《河北医学》
CAS
2020年第3期486-490,共5页
Hebei Medicine
基金
山东省中医药科技发展计划项目，(编号:2017-219)
